Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Smoking Cessation in Patients With Diabetes
NCT07059377Phase 3Recruiting
- Sponsor
- University of Ottawa Heart Institute
- Start
- Feb 2026
- Primary completion
- Dec 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in nicotine dependence, sponsored by University of Ottawa Heart Institute. Started Feb 2026; status: recruiting.
02
Drugs
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT07059377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07059377.